dc.contributor.author | Bilen, MA | |
dc.contributor.author | Rini, BI | |
dc.contributor.author | Voss, MH | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Haanen, JBAG | |
dc.contributor.author | Albiges, L | |
dc.contributor.author | Pagliaro, LC | |
dc.contributor.author | Voog, EG | |
dc.contributor.author | Lam, ET | |
dc.contributor.author | Kislov, N | |
dc.contributor.author | McGregor, BA | |
dc.contributor.author | Lalani, A-KA | |
dc.contributor.author | Huang, B | |
dc.contributor.author | di Pietro, A | |
dc.contributor.author | Krulewicz, S | |
dc.contributor.author | Robbins, PB | |
dc.contributor.author | Choueiri, TK | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-08-22T10:47:51Z | |
dc.date.available | 2022-08-22T10:47:51Z | |
dc.date.issued | 2022-02-15 | |
dc.identifier | 1078-0432.CCR-21-1688 | |
dc.identifier.citation | Clinical Cancer Research, 2022, 28 (4), pp. 738 - 747 | |
dc.identifier.issn | 1078-0432 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5287 | |
dc.identifier.eissn | 1557-3265 | |
dc.identifier.eissn | 1557-3265 | |
dc.identifier.doi | 10.1158/1078-0432.CCR-21-1688 | |
dc.description.abstract | PURPOSE: To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib. EXPERIMENTAL DESIGN: Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component, ≥1 measurable lesions, Eastern Cooperative Oncology Group performance status of 0 or 1, fresh or archival tumor specimen, and adequate renal, cardiac, and hepatic function were included. Retrospective analyses of the association between baseline NLR and progression-free survival (PFS) and overall survival (OS) in the avelumab plus axitinib or sunitinib arms were performed using the first interim analysis of the phase 3 JAVELIN Renal 101 trial (NCT02684006). Multivariate Cox regression analyses of PFS and OS were conducted. Translational data were assessed to elucidate the underlying biology associated with differences in NLR. RESULTS: Patients with below-median NLR had longer observed PFS with avelumab plus axitinib [stratified HR, 0.85; 95% confidence interval (CI), 0.634-1.153] or sunitinib (HR, 0.56; 95% CI, 0.415-0.745). In the avelumab plus axitinib or sunitinib arms, respectively, median PFS was 13.8 and 11.2 months in patients with below-median NLR, and 13.3 and 5.6 months in patients with median-or-higher NLR. Below-median NLR was also associated with longer observed OS in the avelumab plus axitinib (HR, 0.51; 95% CI, 0.300-0.871) and sunitinib arms (HR, 0.30; 95% CI, 0.174-0.511). Tumor analyses showed an association between NLR and key biological characteristics, suggesting a role of NLR in underlying mechanisms influencing clinical outcome. CONCLUSIONS: Current data support NLR as a prognostic biomarker in patients with advanced RCC receiving avelumab plus axitinib or sunitinib. | |
dc.format | Print | |
dc.format.extent | 738 - 747 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER ASSOC CANCER RESEARCH | |
dc.relation.ispartof | Clinical Cancer Research | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Adult | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Axitinib | |
dc.subject | Carcinoma, Renal Cell | |
dc.subject | Humans | |
dc.subject | Kidney Neoplasms | |
dc.subject | Lymphocytes | |
dc.subject | Neutrophils | |
dc.subject | Retrospective Studies | |
dc.subject | Sunitinib | |
dc.title | Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-11-15 | |
dc.date.updated | 2022-08-22T10:46:59Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1158/1078-0432.CCR-21-1688 | |
rioxxterms.licenseref.startdate | 2022-02-15 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/34789480 | |
pubs.issue | 4 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 28 | |
dc.contributor.icrauthor | Larkin, James | |
icr.provenance | Deposited by Mr Arek Surman on 2022-08-22. Deposit type is initial. No. of files: 1. Files: 738.pdf | |